BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32055920)

  • 1. Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia.
    Risnik D; Colado A; Podaza E; Almejún MB; Elías EE; Bezares RF; Fernández-Grecco H; Seija N; Oppezzo P; Borge M; Gamberale R; Giordano M
    Cancer Immunol Immunother; 2020 May; 69(5):813-824. PubMed ID: 32055920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia.
    Cuesta-Mateos C; López-Giral S; Alfonso-Pérez M; de Soria VG; Loscertales J; Guasch-Vidal S; Beltrán AE; Zapata JM; Muñoz-Calleja C
    Exp Hematol; 2010 Sep; 38(9):756-64, 764.e1-4. PubMed ID: 20488224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
    Belgiovine C; Bello E; Liguori M; Craparotta I; Mannarino L; Paracchini L; Beltrame L; Marchini S; Galmarini CM; Mantovani A; Frapolli R; Allavena P; D'Incalci M
    Br J Cancer; 2017 Aug; 117(5):628-638. PubMed ID: 28683469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes.
    Filip AA; Ciseł B; Wąsik-Szczepanek E
    Clin Exp Med; 2015 Feb; 15(1):73-83. PubMed ID: 24337970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.
    Morande PE; Zanetti SR; Borge M; Nannini P; Jancic C; Bezares RF; Bitsmans A; González M; Rodríguez AL; Galmarini CM; Gamberale R; Giordano M
    Invest New Drugs; 2012 Oct; 30(5):1830-40. PubMed ID: 21887502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation.
    Calpe E; Codony C; Baptista MJ; Abrisqueta P; Carpio C; Purroy N; Bosch F; Crespo M
    Blood; 2011 Oct; 118(16):4401-10. PubMed ID: 21865343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration.
    Redondo-Muñoz J; José Terol M; García-Marco JA; García-Pardo A
    Blood; 2008 Jan; 111(1):383-6. PubMed ID: 17890452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia.
    Catusse J; Leick M; Groch M; Clark DJ; Buchner MV; Zirlik K; Burger M
    Mol Cancer; 2010 Nov; 9():297. PubMed ID: 21092185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
    Blunt MD; Koehrer S; Dobson RC; Larrayoz M; Wilmore S; Hayman A; Parnell J; Smith LD; Davies A; Johnson PWM; Conley PB; Pandey A; Strefford JC; Stevenson FK; Packham G; Forconi F; Coffey GP; Burger JA; Steele AJ
    Clin Cancer Res; 2017 May; 23(9):2313-2324. PubMed ID: 27697994
    [No Abstract]   [Full Text] [Related]  

  • 10. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.
    Fiorcari S; Martinelli S; Bulgarelli J; Audrito V; Zucchini P; Colaci E; Potenza L; Narni F; Luppi M; Deaglio S; Marasca R; Maffei R
    Haematologica; 2015 Feb; 100(2):253-62. PubMed ID: 25398834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nurselike cells sequester B cells in disorganized lymph nodes in chronic lymphocytic leukemia via alternative production of CCL21.
    Zaaboub R; Vimeux L; Contremoulins V; Cymbalista F; Lévy V; Donnadieu E; Varin-Blank N; Martin A; Dondi E
    Blood Adv; 2022 Aug; 6(16):4691-4704. PubMed ID: 35679464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia.
    Blanco G; Puiggros A; Sherry B; Nonell L; Calvo X; Puigdecanet E; Chiu PY; Kieso Y; Ferrer G; Palacios F; Arnal M; Rodríguez-Rivera M; Gimeno E; Abella E; Rai KR; Abrisqueta P; Bosch F; Calon A; Ferrer A; Chiorazzi N; Espinet B
    Exp Hematol; 2021 Mar; 95():68-80. PubMed ID: 33421548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia.
    Giannoni P; Cutrona G; Totero D
    Curr Mol Med; 2017; 17(1):24-33. PubMed ID: 28231754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells.
    Chunsong H; Yuling H; Li W; Jie X; Gang Z; Qiuping Z; Qingping G; Kejian Z; Li Q; Chang AE; Youxin J; Jinquan T
    J Immunol; 2006 Nov; 177(10):6713-22. PubMed ID: 17082584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia.
    Alfonso-Pérez M; López-Giral S; Quintana NE; Loscertales J; Martín-Jiménez P; Muñoz C
    J Leukoc Biol; 2006 Jun; 79(6):1157-65. PubMed ID: 16603585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment.
    Schulz A; Dürr C; Zenz T; Döhner H; Stilgenbauer S; Lichter P; Seiffert M
    Blood; 2013 Mar; 121(13):2503-11. PubMed ID: 23349394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL).
    Richardson SJ; Matthews C; Catherwood MA; Alexander HD; Carey BS; Farrugia J; Gardiner A; Mould S; Oscier D; Copplestone JA; Prentice AG
    Blood; 2006 May; 107(9):3584-92. PubMed ID: 16332969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemokines and common variable immunodeficiency; possible contribution of CCL19, CCL21 and CCR7 to immune dysregulation.
    Fevang B; Yndestad A; Damås JK; Halvorsen B; Holm AM; Beiske K; Aukrust P; Frøland SS
    Clin Exp Immunol; 2009 Nov; 158(2):237-45. PubMed ID: 19747210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monocytic MDSC as a source of immunosuppressive cytokines in chronic lymphocytic leukemia (CLL) microenvironment.
    Kowalska W; Bojarska-Junak A
    Folia Histochem Cytobiol; 2020; 58(1):25-36. PubMed ID: 32227331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia.
    Debant M; Burgos M; Hemon P; Buscaglia P; Fali T; Melayah S; Le Goux N; Vandier C; Potier-Cartereau M; Pers JO; Tempescul A; Berthou C; Bagacean C; Mignen O; Renaudineau Y
    J Immunother Cancer; 2019 Apr; 7(1):111. PubMed ID: 31014395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.